Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.49 |
| ▸ | ACHE | P22303 | 3/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.46 |
| ▸ | LIPE | Q05469 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4250549 | 0.89 | FAAH (0.50) | FAAHACHES1PR5LIPEHRH3 | |
| SCHEMBL4241232 | 0.84 | BCHE (0.41) | FAAHACHES1PR5S1PR1DRD3 | |
| SCHEMBL1014404 | 0.80 | S1PR5 (0.50) | FAAHS1PR5S1PR1DRD3 | |
| SCHEMBL8222010 | 0.79 | NPFFR1 (0.49) | S1PR5S1PR1BCHE | |
| SCHEMBL4250544 | 0.73 | BCHE (0.42) | FAAHACHEDRD3BCHE | |
| SCHEMBL5434868 | 0.72 | FUCA1 (0.49) | ACHES1PR5S1PR1BCHE | |
| SCHEMBL30776776 | 0.72 | NPC1 (0.67) | FAAHLIPETAAR1NPC1GAA | |
| SCHEMBL5105573 | 0.72 | CHRM3 (0.46) | S1PR5S1PR1 | |
| SCHEMBL5105568 | 0.72 | CHRM3 (0.46) | S1PR5S1PR1 | |
| SCHEMBL29739424 | 0.72 | ALDH1A1 (0.56) | S1PR5DRD3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | FAAH 633/4885ACHE 108/4885S1PR5 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.